Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients
Launched by ALTHAIA XARXA ASSISTENCIAL UNIVERSITÀRIA DE MANRESA · Sep 16, 2010
Trial Information
Current as of August 24, 2025
Completed
Keywords
ClinConnect Summary
The goal of this proposal is to apply PAV+ as routine ventilatory mode in the early stage of critically ill patients, taking advantages of spontaneous breathing and better patient-ventilator interaction.
The standard treatment in patients with acute respiratory failure is mechanical ventilation in control-mode for the first days of acute illness. This procedure is usually associated with patient-ventilator dyssynchrony, higher needs of sedation and/or relaxation, muscle atrophy, etc. PAV + is a new ventilatory mode that applies pressure in proportion to spontaneous patient inspiratory effo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18 years of age or older
- • Anticipated MV \> 24 hours
- • Availability of informed consent from patient or next of kin
- * Ventilation parameters measured under PAV+ 80% gain:
- • PaO2/FiO2 \>100 RPAV \<10 cm H2O/l/s CPAV \> 30 ml/cm H2O WOBTOT \<1.5 J/l VE \<18 l/min
- Exclusion Criteria:
- • Patients on moribund state or with life-sustaining therapy withholding decision.
- • Patients with unstable respiratory/hemodynamic state, PaO2/FiO2 \<100, Dopamine \>15 microg/Kg/min or epinephrine \>0.1 microg/kg/min.
- • Pregnancy.
- • Air leak.
- • Patients needing deep sedation or muscle paralysis
- • Patients needing hyperventilation (brain trauma).
- • Patients with severe muscle weakness.
- • Recruitment maneuvers or prone position.
About Althaia Xarxa Assistencial Universitària De Manresa
Althaia Xarxa Assistencial Universitària de Manresa is a leading healthcare institution in Catalonia, Spain, dedicated to providing high-quality medical care and advancing clinical research. As a university-affiliated network, Althaia integrates comprehensive healthcare services with academic excellence, fostering innovation and collaboration in the medical field. The organization is committed to improving patient outcomes through rigorous clinical trials and research initiatives, focusing on a wide range of therapeutic areas. With a multidisciplinary team of healthcare professionals, Althaia plays a pivotal role in enhancing evidence-based practices and contributing to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manresa, Catalunya, Spain
Patients applied
Trial Officials
Rafael Fernandez, M.D.
Principal Investigator
Althaia Xarxa Assistencial Universitària de Manresa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials